Autolus reports Q2 AUCATZYL revenue, raises 2026 guidance, secures $250M facility

Autolus Therapeutics plc reported on August 3, 2026 that preliminary Q2 2026 AUCATZYL net product revenue was approximately $45 million with gross margin of approximately 35% year-to-date.¹ The company also said it raised full year 2026 guidance for AUCATZYL net product revenue to $140 million to $150 million, from between $120 million to $135 million.¹

Alongside the revenue update, Autolus entered into a strategic financing with Perceptive Advisors for the sale of notes of up to $250 million in aggregate principal amount in a five-year, interest-only senior credit facility, subject to certain conditions.¹ An initial $75 million principal amount of notes was issued to Perceptive on July 30, 2026, with an additional $25 million available at Autolus's option for up to six months post-closing.¹ A further $150 million in aggregate principal amount may become available in separate tranches upon achievement of certain pre-specified revenue milestones.¹

On terms, the facility bears interest at one month SOFR, subject to a floor of 3.50%, plus 7.25%, and is interest-only until maturity.¹ At closing, Autolus issued Perceptive a warrant for up to 3.5 million ADSs at an exercise price of $1.9314 per ADS, equal to 125% of the 30-day volume-weighted average price before closing.¹

The company said the first two tranches, totaling $100 million, together with its most recently reported cash position, are expected to fund operations into the second quarter of 2028.¹ Autolus is scheduled to report full second quarter 2026 financial results on August 11, 2026.¹ Jefferies International Limited advised Autolus on debt and Cooley served as its legal counsel, while Latham & Watkins advised Perceptive.¹